Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b multi-center, randomized, dose-ranging, double-blind, parallel clinical trial of Halo-Lido cream for the treatment of hemorrhoids

Next Previous
Trial Profile

Phase 2b multi-center, randomized, dose-ranging, double-blind, parallel clinical trial of Halo-Lido cream for the treatment of hemorrhoids

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Jul 2024 According to a Citius Pharmaceuticals Inc media release, an end of Phase 2b trial meeting with the FDA was held to discuss the positive data for Halo-Lido. The data showed a meaningful reduction in symptom severity when compared to individual components alone.
  • 14 Feb 2024 According to a Citius Pharmaceuticals Inc media release, the company has scheduled end of Phase 2b trial meeting with FDA in calendar 2Q 2024 to discuss next steps in development of Halo-Lido for the treatment of hemorrhoids.
  • 14 Aug 2023 According to a Citius Pharmaceuticals Inc media release, company extending financial runway through August 2024 with $15 million in capital raised through a registered direct offering of common stock and warrants at a purchase price of $1.20 per share on May 8, 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top